Quintrio
Home

PHARMACEUTICAL PREPARATIONS

BeyondSpring Inc. Ordinary Shares

BYSI

BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $0.563 – $0.63
Volume 10,614
Market cap $24M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$24.02M
Price / earnings
—
Price / book
-0.68×
Price / sales
—
EV / sales
—
EV / EBITDA
-2.54×

Profitability

Earnings per share
-$0.16
Return on assets
-45.77%
Return on equity
18.8%
Dividend yield
0%

Liquidity and leverage

Debt / equity
-0×
Current ratio
1.66×
Quick ratio
1.66×
Cash ratio
0.45×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$16.75M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for BYSI, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$758K$1.16M$1.12M$751K$947K$1.74M$1.23M$1.74M
Research and development$973K$1.08M$1.47M$1.04M$1M$874K$472K$622K
Total operating expenses$1.73M$2.23M$2.6M$1.79M$1.95M$2.61M$1.7M$2.36M
Operating income-$1.73M-$2.23M-$2.6M-$1.79M-$1.95M-$2.61M-$1.7M-$2.36M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$1.65M-$2.16M-$2.49M-$1.72M-$1.86M-$2.56M-$1.82M-$2.22M
Income taxes$100K$192K$22K$26K$22K$20K$96K$0
Net income-$5.7M-$6.67M-$15.24M-$1.5M-$4.65M$1.17M-$7.1M-$2.22M
Net income attributable to common shareholders-$849K-$2.16M-$2.14M-$1.54M-$1.81M$4.48M-$1.73M-$2.13M
EBITDA-$1.71M-$2.21M-$2.75M-$1.71M-$1.87M-$2.53M-$1.68M-$2.28M
Basic earnings per share-$0.02-$0.05-$0.05-$0.04-$0.04$0.11-$0.04-$0.05
Diluted earnings per share-$0.02-$0.05-$0.05-$0.04-$0.04$0.11-$0.04-$0.05

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path

BeyondSpring presented Phase 3 DUBLIN-3 trial results showing Plinabulin plus docetaxel improved overall survival in Asian patients with EGFR wild-type non-small cell lung cancer, with reduced neutropenia and promising survival rates.

GlobeNewswire Inc.

BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting

BeyondSpring presented updated results from a phase 2 study evaluating a triple combination of pembrolizumab, plinabulin, and docetaxel in metastatic NSCLC patients who progressed on prior immune checkpoint inhibitors. The regimen showed promising efficacy with a disease control rate of 89.3% and median PFS of 8.6 months.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.